Bell, CJ, Nutt, DJ. Serotonin and panic. Br J Psychiatry
1998; 172: 465–71.
Baldwin, DS, Anderson, IM, Nutt, DJ, Bandelow, B, Bond, A, Davidson, JR, den Boer, JA, Fineberg, NA, Knapp, M, Scott, J, Wittchen, HU. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol
2005; 19: 567–96.
Parks, CL, Robinson, PS, Sibille, E, Shenk, T, Toth, M. Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci USA
1998; 95: 10734–9.
Lesch, KP, Wiesmann, M, Hoh, A, Müller, T, Disselkamp-Tietze, J, Osterheider, M, Schulte, HM. 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology (Berl)
1992; 106: 111–7.
Chessick, CA, Allen, MH, Thase, M, Batista Miralha da Cunha, AB, Kapczinski, FF, de Lima, MS, dos Santos Souza, JJ. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev
2006; (3): CD006115.
Neumeister, A, Bain, E, Nugent, AC, Carson, RE, Bonne, O, Luckenbaugh, DA, Eckelman, W, Herscovitch, P, Charney, DS, Drevets, WC. Reduced serotonin type 1A binding in panic disorder. J Neurosci
2004; 24: 589–91.
Carson, RE, Wu, Y, Lang, L, Ma, Y, Der, MG, Herscovitch, P, Eckelman, WC. Brain uptake of the acid metabolites of F-18-labelled WAY100635 analogs. J Cereb Blood Flow Metab
2003; 23: 249–60.
Lanzenberger, RR, Mitterhauser, M, Spindelegger, C, Wadsak, W, Klein, N, Mien, LK, Holik, A, Attarbaschi, T, Mossaheb, N, Sacher, J, Geiss-Granadia, T, Kletter, K, Kasper, S, Tauscher, J. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry
2007; 61: 1081–9.
Pike, VW, McCarron, JA, Lammertsma, AA, Osman, S, Hume, SP, Sargent, PA, Bench, CJ, Cliffe, IA, Fletcher, A, Grasby, PM. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635. Eur J Pharmacol
1996; 301: R5–7.
Gunn, RN, Sargent, PA, Bench, CJ, Rabiner, EA, Osman, S, Pike, VW, Hume, SP, Grasby, PM, Lammertsma, AA. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage
1998; 8: 426–40.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). APA, 2004.
Guy, W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76–338. National Institute of Mental Health, 1976: 179–222.
First, MB, Spitzer, RL, Gibbon, M, Williams, J. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Patient Edition (SCID–P). New York State Psychiatric Institute, Biometrics Research, 1997.
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry
1960; 23: 56–62.
Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry
1961; 4: 561–71.
Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol
1959; 32: 50–5.
Sargent, PA, Kjaer, KH, Bench, CJ, Rabiner, EA, Messa, C, Meyer, J, Gunn, RN, Grasby, PM, Cowen, PJ. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry
2000; 57: 174–80.
Rabiner, EA, Messa, C, Sargent, PA, Husted-Kjaer, K, Montgomery, A, Lawrence, AD, Bench, CJ, Gunn, RN, Cowen, P, Grasby, PM. A database of [(11)C] WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage
2002; 15: 620–32.
Rosen, JB, Schulkin, J. From normal fear to pathological anxiety. Psychol Rev
1998; 105: 325–50.
Cannistraro, PA, Rauch, SL. Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacol Bull
2003; 37: 8–25.
Blier, P, Ward, NM. Is there a role for 5-HT1A agonists in the treatment of depression?
2003; 53: 193–203.
Bell, C, Forshall, S, Adrover, M, Nash, J, Hood, S, Argyropoulos, S, Rich, A, Nutt, DJ. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol
2002; 16: 5–14.
Argyropoulos, SV, Hood, SD, Adrover, M, Bell, CJ, Rich, AS, Nash, JR, Rich, NC, Witchel, HJ, Nutt, DJ. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry
2004; 56: 503–9.
Gross, C, Zhuang, X, Stark, K, Ramboz, S, Oosting, R, Kirby, L, Santarelli, L, Beck, S, Hen, R. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature
2002; 416: 396–400.
Gorman, JM, Kent, JM, Sullivan, GM, Coplan, JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry
2000; 157: 493–505.
Malizia, AL. Brain imaging and anxiety disorders. In Anxiety Disorders (eds Nutt, DJ & Ballenger, JC): 201–28. Blackwell Science, 2003.
Malizia, AL, Cunningham, VJ, Bell, CJ, Liddle, PF, Jones, T, Nutt, DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry
1998; 55: 715–20.
Maron, E, Kuikka, JT, Shlik, J, Vasar, V, Vanninen, E, Tiihonen, J. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res
2004; 132: 173–81.
Bailey, JE, Argyropoulos, SV, Lightman, SL, Nutt, DJ. Does the brain noradrenaline network mediate the effects of the CO2 challenge?
2003; 17: 252–9.
Kent, JM, Coplan, JD, Mawlawi, O, Martinez, JM, Browne, ST, Slifstein, M, Martinez, D, Abi-Dargham, A, Laruelle, M, Gorman, JM. Prediction of panic response to a respiratory stimulant by reduced orbitofrontal cerebral blood flow in panic disorder. Am J Psychiatry
2005; 162: 1379–81.
Drevets, WC, Frank, E, Price, JC, Kupfer, DJ, Greer, PJ, Mathis, C. Serotonin type-1A receptor imaging in depression. Nucl Med Biol
2000; 27: 499–507.
McKittrick, CR, Blanchard, DC, Blanchard, RJ, McEwen, BS, Sakai, RR. Serotonin receptor binding in a colony model of chronic social stress. Biol Psychiatry
1995; 37: 383–93.
Ase, AR, Reader, TA, Hen, R, Riad, M, Descarries, L. Regional changes in density of serotonin transporter in the brain of 5-HT1A and 5-HT1B knockout mice, and of serotonin innervation in the 5-HT1B knockout. J Neurochem
2001; 78: 619–30.
Welner, SA, De Montigny, C, Desroches, J, Desjardins, P, Suranyi-Cadotte, BE. Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant drug treatment. Synapse
1989; 4: 347–52.
Li, Q, Brownfield, MS, Levy, AD, Battaglia, G, Cabrera, TM, Van de Kar, LD. Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats. Biol Psychiatry
1994; 36: 300–8.
Hensler, JG, Kovachich, GB, Frazer, A. A quantitative autoradiographic study of serotonin1A receptor regulation: effect of 5,7-dihydroxytryptamine and antidepressant treatments. Neuropsychopharmacology
1991; 4: 131–44.
Le Poul, E, Lima, L, Laporte, AM, Even, C, Doucet, E, Fattaccini, CM, Laaris, N, Hamon, M, Lanfumey, L. Central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors: comparison between fluoxetine and paroxetine [French]. Encephale
1995; 21: 123–32.
Li, Q, Muma, NA, Van de Kar, LD. Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and Go proteins and in endocrine responses to 5-HT1A agonist. JPharmacol Exp Ther
1996; 279: 1035–42.
Li, Q, Muma, NA, Battaglia, G, Van de Kar, LD. A desensitization of hypothalamic 5-HT1A receptors by repeated injections of paroxetine: reduction in the levels of Gi and Go proteins and neuroendocrine responses, but not in the density of 5-HT1A receptors. J Pharmacol Exp Ther
1997; 283: 1581–90.
Duman, RS. Depression: a case of neuronal life and death?
2004; 56: 140–5.
Lanzenberger, R, Wadsak, W, Spindelegger, C, Mitterhauser, M, Klein, N, Mien, LK, Attarbaschi, T, Mossaheb, N, Sacher, J, Holik, A, Geiss-Granadia, T, Kletter, K, Kasper, S. Hippocampal serotonin-1A receptor binding correlates with cortisol plasma levels in social anxiety disorder. Eur Neuropsychopharmacol
2006; 16 (suppl 4): S270.
Steciuk, M, Kram, M, Kramer, GL, Petty, F. Acute stress does not alter 5-HT1A receptor density. Prog Neuropsychopharmacol Biol Psychiatry
2000; 24: 155–61.